BBlogFlow

How AI Helped One Family Navigate a Complex Medical Journey - HCI Innovation Group

·Oct 10, 2026
Source: HCI Innovation Group
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

On October 8 in Albuquerque, at the second annual summit hosted by New Mexico-based HealthInno, a health tech studio and statewide health innovation network, thought leaders, medical professionals, business executives, and subject matter experts gathered to discuss and learn about artificial intelligence (AI) in healthcare and the future of healthcare innovation.

After the opening remarks, Stefany Goradia, advisor at HealthInno and head of Population Health & Data at the UNM Center for Health Policy, shared her family’s healthcare journey with the audience and the points where it broke down. She asked the audience to keep this story in mind throughout the day as they learned about health AI and innovation. Pietje Kobus-McAllisterStefany Goradia, advisor at HealthInno and head of Population Health & Data at the UNM Center for Health Policy, addresses the audience at HealthInno's second annual summit in Albuquerque, New MexicoAfter Goradia’s father was hospitalized with sepsis, heart complications, and kidney problems, his family began collecting lab results, medical records, medication changes, and home monitoring data.

This article is an excerpt. To read the full content, visit the original source. HCI Innovation Group

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·